Therapy Areas: Inflammatory Diseases
Medac Pharma ends patent challenge of Rasuvo following PTAB's decision
12 February 2018 -

Pharmaceutical company Medac Pharma Inc stated on Friday that the Patent Trial And Appeal Board (PTAB) has decided to uphold the patentability of all the claims of its '231 patent" for Rasuvo.

The company said the PTAB has upheld all 22 claims that belongs to its parent company medac GmbH's patent covering its rheumatoid arthritis treatment, Rasuvo, an auto-injector that provides highly concentrated doses of methotrexate.

Following the PTAB ruling, Medac now ends the patent challenge brought by Koios Pharmaceuticals LLC.

According to the company's CEO Terri Shoemaker, the patent, which is based on Medac's pioneering work to bring methotrexate treatment to patients in need of safe, less painful, and easy to use form, does not expire until 2029.

Login
Username:

Password: